The DOI matches its Crossref record; 145 of the 147 references it cites were found in a registry or an index; 45 of the 103 sources its claims cite were checked for support.
2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery
Open accessAbstract
Major updates to 1991 National Institutes of Health guidelines for bariatric surgery Metabolic and bariatric surgery (MBS) is recommended for individuals with a body mass index (BMI) > 35 kg/m 2 , regardless of presence, absence, or severity of co-morbidities. MBS should be considered for individuals with metabolic disease and BMI of 30-34.9 kg/m 2 . BMI thresholds should be adjusted in the Asian population such that a BMI > 25 kg/m 2 suggests clinical obesity, and individuals with BMI > 27.5 kg/m 2 should be offered MBS. Long-term results of MBS consistently demonstrate safety and efficacy. Appropriately selected children and adolescents should be considered for MBS. (Surg Obes Relat Dis 2022; https://doi.org/10.1016/j.soard.2022.08.013 ) © 2022 American Society for Metabolic and Bariatric Surgery. All rights reserved.
Overview
CoChat Summary
TL;DR
This 2022 ASMBS/IFSO joint statement updates indications for metabolic and bariatric surgery (MBS), recommending MBS for BMI >35 kg/m² regardless of co-morbidities and considering it for BMI 30–34.9 kg/m² with metabolic disease after failed nonsurgical therapy. It also adjusts BMI thresholds for Asian populations, supports carefully selected children/adolescents, and summarizes evidence for safety, efficacy, and durability.
Key findings
- MBS is recommended for individuals with BMI >35 kg/m² regardless of presence, absence, or severity of co-morbidities; it should be considered for BMI 30–34.9 kg/m² with metabolic disease, especially type 2 diabetes, when nonsurgical methods fail.
- In Asian populations, clinical obesity is recognized at BMI >25 kg/m², and MBS should be offered at BMI >27.5 kg/m²; access should not be denied solely by traditional BMI thresholds.
- Pediatric/adolescent MBS should be considered for BMI >120% of the 95th percentile with a major co-morbidity, or BMI >140% of the 95th percentile, after multidisciplinary evaluation.
- Reported benefits include perioperative mortality of 0.03–0.2%, durable weight loss generally >60% excess weight loss, cancer risk reduction of 11–50% for all cancer types, 32% lower cancer risk and 48% lower cancer-related death in a >30,000-patient cohort, and mortality reductions such as 30.7% in the Swedish Obese Subjects study and 40% after RYGB in another cohort.
Methods
- Design: joint ASMBS/IFSO consensus statement and clinical guideline updating the 1991 NIH Consensus Statement on gastrointestinal surgery for severe obesity.
- Data/sample: narrative synthesis of published literature, prior society statements, and expert consensus; no primary patient sample, systematic search, or meta-analysis is described.
- Main analysis: expert interpretation of evidence on BMI thresholds, age extremes, high-risk patients, bridge-to-transplant/surgery indications, outcomes, and revisional surgery to produce recommendations.
Limitations
- The paper states that BMI has limitations for accurately risk-stratifying patients with obesity, that there is a paucity of data on surgical outcomes in patients with clinically significant portal hypertension, and that there is no consensus on the best procedure for individuals with especially high BMI.
- The paper notes that evidence for cancer risk reduction may attenuate over time and that confounding by operation type, cancer type, health behaviors, and co-morbidities is unclear.
- Evident from the text: this is a consensus/narrative guideline rather than a systematic review, and no formal search strategy, evidence grading, or quantitative synthesis is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Valid · 0 Not valid · 25 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“At the same time, obesity conveys a 3-fold increase in the risk of liver decompensation in patients with known cirrhosis [94].”
§ 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery > MBS in the high-risk patient > Cirrhosis
What the sources say
- Supportedcites [94] Patton H, Heimbach J, McCullough A. AGA clinical practice update on bariatric surgery in cirrhosis: expert review. Clin Gastroenterol Hepatol. 2021;19(3):436–45. source
The section “How does obesity impact chronic liver disease?” reports clinical decompensation rates of 43% in obese patients with cirrhosis and 14% in normal-weight patients with cirrhosis—approximately a threefold difference. No page number is provided in our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple studies have shown that MBS reduces the risk of developing cancer in the population with class II/III obesity, ranging from 11% to 50% for all cancer types [130, 134–137].”
§ 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery > Outcomes > Cancer risk
What the sources say
- Partly supportedcites [130] Schauer DP, Feigelson HS, Koebnick C, Caan B, Weinmann S, Leonard AC, Powers JD, Yenumula PR, Arterburn DE. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann Surg. 2019;269(1):95–101. sourceExperimental — accuracy not yet measured
The Results (page not available) report a 33% lower hazard of developing any cancer after bariatric surgery in a cohort with BMI ≥35 kg/m². The Discussion (page not available) also reports lower total cancer incidence in prior studies. This source supports the general finding, but not the full stated 11%–50% range; as an observational study, it describes an association rather than establishing that surgery causes the reduction. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [134] Adams TD, Hunt SC. Cancer and obesity: Effect of bariatric surgery. World J Surg. 2009;33(10):2028–33. source
- Not checked — no full text of the sourcecites [135] Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653–62. source
- Partly supportedcites [136] Anveden A, Taube M, Peltonen M, Jacobson P, Andersson-Assarsson JC, Sjöholm K, Svensson PA, Carlsson LMS. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study. Gynecol Oncol. 2017;145(2):224–9. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report an overall-cancer hazard ratio of 0.71 after bariatric surgery, a 29% lower risk within the claimed 11%–50% range. The Methods (page unavailable) specify women aged 37–60 with BMI >38 kg/m², and the Introduction says the earlier SOS finding showed a reduction in women but not men. This paper therefore supports one result within the range, not the range itself or a reduction across the whole class II/III obesity population. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [137] Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022;327(24):2423–33. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Representative studies include the Swedish Obese Subjects study demonstrated an adjusted decreased overall mortality by 30.7% in the group of 2010 surgical patients compared with nonsurgical controls, at an average of 10 years after surgery [17].”
§ 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery > Outcomes > Mortality
What the sources say
- Partly supportedcites [17] Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52. sourceExperimental — accuracy not yet measured
The Abstract reports 2,010 surgical patients, 2,037 controls, and a mean follow-up of 10.9 years. The Overall Mortality section reports lower mortality after surgery, but its adjusted hazard ratio of 0.71 corresponds to an approximately 29% reduction in mortality hazard, not the claimed 30.7%. (LLM, conf=0.90)
boostedstates a causen = 2,010- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“After surgery, the significant improvement of metabolic disease, as well as the decrease in overall mortality, has been reported in multiple studies further supporting the importance of this treatment modality [15–19].”
§ 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery > Abstract
What the sources say
- Supportedcites [15] Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39(6):902–11. source
The Abstract reports that a review of 12 cohort-matched studies broadly supports an all-cause mortality benefit after bariatric surgery; all but two found a lower mortality rate in surgical patients. This supports the citing sentence’s wording that a decrease has been reported in multiple studies. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [16] Arterburn DE, Olsen MK, Smith VA, Livingston EH, van Scoyoc L, Yancy Jr WS, Eid G, Weidenbacher H, Maciejewski ML. Association between bariatric surgery and long-term survival. JAMA. 2015;313(1):62–70. source
- Supportedcites [17] Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52. source
The Overall Mortality section reports fewer deaths in the surgery group than in the control group (101 versus 129) and a hazard ratio of 0.76 (P = 0.04). The Discussion describes bariatric surgery as associated with reduced overall mortality compared with conventional treatment. (LLM, conf=0.94)
- Could not verifycites [18] Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;26(20):2031–42. sourceExperimental — accuracy not yet measured
The Primary End Points and Abstract report lower risks of composite liver and cardiovascular outcomes after bariatric surgery; those composites include cause-specific deaths, but they are not measures of overall mortality. A search for all-cause mortality, survival, and deaths found no comparison showing a decrease in overall mortality. (LLM, conf=0.76)
- Supportedcites [19] Aminian A, Zajicheck A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322(13):1271–82. source
The Secondary End Points section reports lower all-cause mortality in the metabolic-surgery group than in the nonsurgical group: 10.0% versus 17.8% cumulative incidence at eight years. The Discussion describes this as an association in an observational study of patients with type 2 diabetes and obesity, rather than proof that surgery caused the reduction. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“After surgery, the significant improvement of metabolic disease, as well as the decrease in overall mortality, has been reported in multiple studies further supporting the importance of this treatment modality [15–19].”
§ 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery > Abstract
What the sources say
- Supportedcites [15] Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39(6):902–11. source
The Conclusions state that metabolic surgery can significantly improve glycemic control in patients with type 2 diabetes and consistently improves weight and cardiovascular risk factors. This supports the attributed claim of improvement in metabolic disease after surgery. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [16] Arterburn DE, Olsen MK, Smith VA, Livingston EH, van Scoyoc L, Yancy Jr WS, Eid G, Weidenbacher H, Maciejewski ML. Association between bariatric surgery and long-term survival. JAMA. 2015;313(1):62–70. source
- Supportedcites [17] Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52. source
The Discussion reports that earlier analyses of the same study found beneficial effects of bariatric surgery on diabetes and other cardiovascular risk factors, supporting the claim about metabolic improvement. It also reports a marked reduction in overall mortality. The paper does not present the metabolic outcomes as new results of this mortality analysis. (LLM, conf=0.87)
- Supportedcites [18] Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;26(20):2031–42. source
The Abstract states that bariatric surgery improves hyperglycemia, hypertension, and dyslipidemia in patients with obesity and metabolic disease. The Status of Obesity and Diabetes Over Time section also reports a significant reduction in hemoglobin A1c among patients with diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Supportedcites [19] Aminian A, Zajicheck A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322(13):1271–82. source
The ‘Status of Obesity, Diabetes, and Medications Over Time’ section reports a significant reduction in HbA1c and lower use of diabetes medications after metabolic surgery compared with usual care. The ‘Secondary End Points’ section also reports lower all-cause mortality. These findings support the cited sentence for patients with type 2 diabetes and obesity, although the study reports associations rather than proving causation. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
24 more claims · 6 with their cited sources checked
Create a free account to see all 51 claims and every source verdict.
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For Asian populations, the threshold is lower, with MBS indicated for a BMI greater than 27.5 kg/m2 [13,25].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Metabolic and bariatric surgery (MBS), including RYGB, is currently recommended for individuals with a body mass index (BMI) greater than 35 kg/m2 irrespective of comorbidities, and also for patients with a BMI between 30 and 34.9 kg/m2 who present with metabolic disease.”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 1×
“7% in the group of 2010 surgical patients compared with nonsurgical controls, at an average of 10 years after surgery [17].”
BackgroundLifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Body Fatness and Cancer — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1606602 · Cited by 3,596
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934 · cited 14×
“Furthermore, data suggest that the benefits of RYGB on T2D and hypertension are greater in adolescents than adults [52–55].”
BackgroundMethodResultInfluentialSelf-citationLong-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Research works printed but not linked: 1
- Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361(5):445–54. · DOI · Paper page
Cited by
Definition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Self-citationle Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00356-x · Cited by 237
Protein Nutrition: Understanding Structure, Digestibility, and Bioavailability for Optimal Health
Ajomiwe, N. I., Boland, M., Phongthai, S., Bagiyal, M., Singh, J., & Kaur, L. (2024) · Foods · doi:10.3390/foods13111771 · Cited by 193
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Heart Failure and Obesity: The Latest Pandemic
Aryee, E. K., Özkan, B., & Ndumele, C. E. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.05.003 · Cited by 104
Metadata
- Authors
- Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., de Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., Himpens, J. M., Kow, L., Kurian, M., Loi, K., Mahawar, K., Nimeri, A., O’Kane, M., Papasavas, P. K., Ponce, J., Pratt, J. S. A., Rogers, A. M., Steele, K. E., Suter, M., & Kothari, S. N.
- Affiliations
- VA Palo Alto Health Care System (US)
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- University of Naples Federico II (IT)
- Hospital Alemão Oswaldo Cruz (BR)
- Jordan Hospital (JO)
- Centre Hospitalier Interrégional Edith Cavell (BE)
- Flinders University (AU)
- New York University (US)
- Sutherland Hospital (AU)
- Sunderland Royal Hospital (GB)
- University of North Carolina at Charlotte (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Hartford Hospital (US)
- CHI Memorial Medical Group (US)
- Lucile Packard Children's Hospital (US)
- Penn State Milton S. Hershey Medical Center (US)
- National Institutes of Health (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Prisma Health (US)
- Corresponding author
- Eisenberg, Dan
- ORCID
- Eisenberg, Dan
- Shikora, Scott A.
- Aarts, Edo
- Aminian, Ali
- Angrisani, Luigi
- Cohen, Ricardo V.
- Goodpaster, Kasey P.S.
- Haddad, Ashraf
- Himpens, Jacques M.
- Kow, Lilian
- Kurian, Marina
- Loi, Ken
- Mahawar, Kamal
- Nimeri, Abdelrahman
- O’Kane, Mary
- Papasavas, Pavlos K.
- Ponce, Jaime
- Pratt, Janey S. A.
- Rogers, Ann M.
- Steele, Kimberley E.
- Suter, Michel
- Kothari, Shanu N.
- Venue
- Obesity Surgery
- Published
- 2022-11-07
- Volume
- 33
- Issue
- 1
- Pages
- 3-14
- ISSN
- 0960-8923 (ISSN-L)
- 1708-0428
- PMC
- PMC9834364
- OpenAlex
- W4308295896
- Semantic Scholar
- 1f18d15b1f21717f39b3306962e1b923ae1b2929
- Cited by
- 768
- References
- 147
- Citations by year
- 2026: 214 · 2025: 233 · 2024: 211 · 2023: 104 · 2022: 4
- FWCI
- 117.54
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-11-29)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Obesity Surgery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS (submittedVersion, cc-by)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by)
- Greater South Information System
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Body Contouring and Surgery
- Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
- Keywords
- bariatric surgery, surgical indications
- MeSH terms
- Adolescent, Child, Humans, Metabolic Diseases, Obesity, Obesity, Morbid, United States, Body Mass Index, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. https://app.cochat.ai/papers/10.1007/s11695-022-06332-1
- The paper
- Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., de Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., Himpens, J. M., Kow, L., Kurian, M., Loi, K., Mahawar, K., Nimeri, A., O’Kane, M., Papasavas, P. K., Ponce, J., . . . Kothari, S. N. (2023). 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obesity Surgery. https://doi.org/10.1007/s11695-022-06332-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.